MENU
MAZE
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Maze Therapeutics (MAZE) Ownership - Who owns Maze Therapeutics?
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
696.35M
P/E Ratio
191.34
Total Cash
264.54M
Projected Growth
N/A
Total Debt
25.01M
Revenue
2.5M
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
6.03
Total Debt/Equity
N/A
Revenue/Share
0.06 USD as % of share price
Fundamentals
MAZE
Capitalization
696M
P/E Ratio
191.34
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
265M
Total Cash/Share
6.03
Total Debt
25M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.06%
Revenue
2.5M
ROE
N/A
Book Value
262M
P/B Ratio
2.66
Cash Flow
N/A
Earnings
-1.68
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
44K
Current Ratio
13.63
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-123M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-28.42
Shares Held By Institutions
417M
Shares Outstanding - Current
43.9M
Total Liabilities
41.3M
Total Volume MTD
N/A
Value
-1
Gain YTD
N/A
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. MAZE showed earnings on August 12, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information